Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Pharmaceuticals filed its first new drug application for azetukalner to treat focal-onset seizures, a key regulatory milestone for the biotech. However, the company paused portions of its late-stage psychiatry program to assess changes aimed at improving tolerability, creating uncertainty around that pipeline segment.